APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Peptide-Radionuclide Conjugates (PRCs)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide-Radionuclide Conjugates (PRCs) Market Outlook and Growth Opportunities 2026

29 December 2025192 pages

Choose your research edition.

Industry ResearchPeptide-Radionuclide Conjugates (PRCs) Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-Radionuclide Conjugates (PRCs) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Peptide-Radionuclide Conjugates (PRCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-Radionuclide Conjugates (PRCs) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-Radionuclide Conjugates (PRCs) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Peptide-Radionuclide Conjugates (PRCs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide-Radionuclide Conjugates (PRCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide-Radionuclide Conjugates (PRCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide-Radionuclide Conjugates (PRCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide-Radionuclide Conjugates (PRCs) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide-Radionuclide Conjugates (PRCs) market include Grand Pharmaceutical, Novartis, Telix Pharmaceutical, RadioMedix, ITM Radiopharma and Curium Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide-Radionuclide Conjugates (PRCs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide-Radionuclide Conjugates (PRCs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide-Radionuclide Conjugates (PRCs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide-Radionuclide Conjugates (PRCs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide-Radionuclide Conjugates (PRCs) Segment by Company

Grand Pharmaceutical

Novartis

Telix Pharmaceutical

RadioMedix

ITM Radiopharma

Curium Pharma

Peptide-Radionuclide Conjugates (PRCs) Segment by Type

Diagnostic PRCs

Therapeutic PRCs

Peptide-Radionuclide Conjugates (PRCs) Segment by Application

Prostate Cancer

Neuroendocrine Tumors

Other

Peptide-Radionuclide Conjugates (PRCs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide-Radionuclide Conjugates (PRCs) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peptide-Radionuclide Conjugates (PRCs) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide-Radionuclide Conjugates (PRCs) significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide-Radionuclide Conjugates (PRCs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Radionuclide Conjugates (PRCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-Radionuclide Conjugates (PRCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Radionuclide Conjugates (PRCs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide-Radionuclide Conjugates (PRCs) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide-Radionuclide Conjugates (PRCs) industry.

Chapter 3: Detailed analysis of Peptide-Radionuclide Conjugates (PRCs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peptide-Radionuclide Conjugates (PRCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peptide-Radionuclide Conjugates (PRCs) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide-Radionuclide Conjugates (PRCs) Industry Trends Table 2. Peptide-Radionuclide Conjugates (PRCs) Industry Drivers Table 3. Peptide-Radionuclide Conjugates (PRCs) Industry Opportunities and Challenges Table 4. Peptide-Radionuclide Conjugates (PRCs) Industry Restraints Table 5. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Company (2021-2026) Table 7. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share by Company (2021-2026) Table 9. Global Peptide-Radionuclide Conjugates (PRCs) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Peptide-Radionuclide Conjugates (PRCs) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peptide-Radionuclide Conjugates (PRCs) Key Company Manufacturing Base & Headquarters Table 12. Global Peptide-Radionuclide Conjugates (PRCs) Company, Product Type & Application Table 13. Global Peptide-Radionuclide Conjugates (PRCs) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide-Radionuclide Conjugates (PRCs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Diagnostic PRCs Table 18. Significant Companies of Therapeutic PRCs Table 19. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share by Type (2021-2026) Table 23. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share by Type (2027-2032) Table 24. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type (2021-2026) Table 28. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Prostate Cancer Table 30. Significant Companies of Neuroendocrine Tumors Table 31. Significant Companies of Other Table 32. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share by Application (2021-2026) Table 36. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share by Application (2027-2032) Table 37. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application (2021-2026) Table 41. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application (2027-2032) Table 42. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2026) & (K Units) Table 44. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2021-2026) Table 45. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2027-2032) & (K Units) Table 46. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2027-2032) Table 47. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Region (2021-2026) Table 50. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Region (2027-2032) Table 52. Global Peptide-Radionuclide Conjugates (PRCs) Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Peptide-Radionuclide Conjugates (PRCs) Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units) Table 57. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021-2026) Table 58. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032) & (K Units) Table 59. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2027-2032) Table 60. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Market Share by Country (2021-2026) Table 62. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Market Share by Country (2027-2032) Table 64. Grand Pharmaceutical Company Information Table 65. Grand Pharmaceutical Business Overview Table 66. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 68. Grand Pharmaceutical Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 73. Novartis Recent Development Table 74. Telix Pharmaceutical Company Information Table 75. Telix Pharmaceutical Business Overview Table 76. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 78. Telix Pharmaceutical Recent Development Table 79. RadioMedix Company Information Table 80. RadioMedix Business Overview Table 81. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 83. RadioMedix Recent Development Table 84. ITM Radiopharma Company Information Table 85. ITM Radiopharma Business Overview Table 86. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 88. ITM Radiopharma Recent Development Table 89. Curium Pharma Company Information Table 90. Curium Pharma Business Overview Table 91. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 93. Curium Pharma Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Peptide-Radionuclide Conjugates (PRCs) Distributors List Table 97. Peptide-Radionuclide Conjugates (PRCs) Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Peptide-Radionuclide Conjugates (PRCs) Product Image Figure 2. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peptide-Radionuclide Conjugates (PRCs) Sales (2021-2032) & (K Units) Figure 5. Global Peptide-Radionuclide Conjugates (PRCs) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Peptide-Radionuclide Conjugates (PRCs) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Diagnostic PRCs Image Figure 10. Therapeutic PRCs Image Figure 11. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share by Type (2021-2032) Figure 14. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type (2021-2032) Figure 17. Prostate Cancer Image Figure 18. Neuroendocrine Tumors Image Figure 19. Other Image Figure 20. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share by Application (2021-2032) Figure 23. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application (2021-2032) Figure 26. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032) & (US$ Million) Figure 31. North America Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032) & (US$ Million) Figure 37. South America Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Peptide-Radionuclide Conjugates (PRCs) Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Peptide-Radionuclide Conjugates (PRCs) Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic PRCs
  • Therapeutic PRCs
Applications
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Other
Companies covered
  • Grand Pharmaceutical
  • Novartis
  • Telix Pharmaceutical
  • RadioMedix
  • ITM Radiopharma
  • Curium Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032)
  4. 1.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume (2021-2032)
  5. 1.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peptide-Radionuclide Conjugates (PRCs) Market Dynamics
  1. 2.1 Peptide-Radionuclide Conjugates (PRCs) Industry Trends
  2. 2.2 Peptide-Radionuclide Conjugates (PRCs) Industry Drivers
  3. 2.3 Peptide-Radionuclide Conjugates (PRCs) Industry Opportunities and Challenges
  4. 2.4 Peptide-Radionuclide Conjugates (PRCs) Industry Restraints
3 Peptide-Radionuclide Conjugates (PRCs) Market by Company
  1. 3.1 Global Peptide-Radionuclide Conjugates (PRCs) Company Revenue Ranking in 2025
  2. 3.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Company (2021-2026)
  3. 3.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Company (2021-2026)
  4. 3.4 Global Peptide-Radionuclide Conjugates (PRCs) Average Price by Company (2021-2026)
  5. 3.5 Global Peptide-Radionuclide Conjugates (PRCs) Company Ranking (2024-2026)
  6. 3.6 Global Peptide-Radionuclide Conjugates (PRCs) Company Manufacturing Base and Headquarters
  7. 3.7 Global Peptide-Radionuclide Conjugates (PRCs) Company Product Type and Application
  8. 3.8 Global Peptide-Radionuclide Conjugates (PRCs) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peptide-Radionuclide Conjugates (PRCs) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peptide-Radionuclide Conjugates (PRCs) Market by Type
  1. 4.1 Peptide-Radionuclide Conjugates (PRCs) Type Introduction
  2. 4.1.1 Diagnostic PRCs
  3. 4.1.2 Therapeutic PRCs
  4. 4.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Type
  5. 4.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Type
  9. 4.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type (2021-2032)
5 Peptide-Radionuclide Conjugates (PRCs) Market by Application
  1. 5.1 Peptide-Radionuclide Conjugates (PRCs) Application Introduction
  2. 5.1.1 Prostate Cancer
  3. 5.1.2 Neuroendocrine Tumors
  4. 5.1.3 Other
  5. 5.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Application
  6. 5.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Application
  10. 5.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application (2021-2032)
6 Peptide-Radionuclide Conjugates (PRCs) Regional Sales and Value Analysis
  1. 6.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021-2026
  4. 6.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2027-2032)
  5. 6.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Region (2027-2032)
  9. 6.5 Global Peptide-Radionuclide Conjugates (PRCs) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032)
  12. 6.6.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032)
  15. 6.7.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032)
  21. 6.9.2 South America Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Country, 2025 VS 2032
7 Peptide-Radionuclide Conjugates (PRCs) Country-level Sales and Value Analysis
  1. 7.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
  4. 7.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026)
  5. 7.3.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032)
  6. 7.4 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peptide-Radionuclide Conjugates (PRCs) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peptide-Radionuclide Conjugates (PRCs) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Grand Pharmaceutical
  2. 8.1.1 Grand Pharmaceutical Company Information
  3. 8.1.2 Grand Pharmaceutical Business Overview
  4. 8.1.3 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  6. 8.1.5 Grand Pharmaceutical Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Peptide-Radionuclide Conjugates (PRCs) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Telix Pharmaceutical
  14. 8.3.1 Telix Pharmaceutical Company Information
  15. 8.3.2 Telix Pharmaceutical Business Overview
  16. 8.3.3 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  18. 8.3.5 Telix Pharmaceutical Recent Developments
  19. 8.4 RadioMedix
  20. 8.4.1 RadioMedix Company Information
  21. 8.4.2 RadioMedix Business Overview
  22. 8.4.3 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  24. 8.4.5 RadioMedix Recent Developments
  25. 8.5 ITM Radiopharma
  26. 8.5.1 ITM Radiopharma Company Information
  27. 8.5.2 ITM Radiopharma Business Overview
  28. 8.5.3 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  30. 8.5.5 ITM Radiopharma Recent Developments
  31. 8.6 Curium Pharma
  32. 8.6.1 Curium Pharma Company Information
  33. 8.6.2 Curium Pharma Business Overview
  34. 8.6.3 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  36. 8.6.5 Curium Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide-Radionuclide Conjugates (PRCs) Value Chain Analysis
  2. 9.1.1 Peptide-Radionuclide Conjugates (PRCs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide-Radionuclide Conjugates (PRCs) Sales Mode & Process
  6. 9.2 Peptide-Radionuclide Conjugates (PRCs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide-Radionuclide Conjugates (PRCs) Distributors
  9. 9.2.3 Peptide-Radionuclide Conjugates (PRCs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst